Notable
MRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
Primary endpoint(s) modified
ModernaTX, Inc.Phase 4 NCT07266558 Registry history of NCT07266558 on ClinicalTrials.gov (opens the registry)